Durable response to EGFR tyrosine kinase inhibitors in a patient with non–small cell lung cancer harboring an EGFR kinase domain duplication

Abstract Epidermal growth factor receptor (EGFR) kinase domain duplication (KDD) has been identified as an oncogenic driver in 0.05% to 0.14% of non–small cell lung cancer (NSCLC) patients. However, little is known of the efficacy of EGFR tyrosine kinase inhibitors (TKIs) for such patients. Here, we...

Повний опис

Бібліографічні деталі

Автори:	Esuteru Hirokawa, Satomi Watanabe, Kazuko Sakai, Masayuki Takeda, Chihiro Sato, Takayuki Takahama, Kazuto Nishio, Kazuhiko Nakagawa
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Wiley 2021-08-01
Серія:	Thoracic Cancer
Предмети:	carcinomatous meningitis epidermal growth factor receptor (EGFR) kinase domain duplication tyrosine kinase inhibitor (TKI)
Онлайн доступ:	https://doi.org/10.1111/1759-7714.14081
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!